Literature DB >> 10101798

p53-dependent cell cycle control: response to genotoxic stress.

D Schwartz1, V Rotter.   

Abstract

p53 protein is involved in key responses to genotoxic stress. These functions underlie the role of p53 as the 'guardian of the genome'. In a simplified manner, upon low or repairable levels of DNA damage, p53 mediates the delay or arrest at checkpoints preceding cell replication (the G1/S checkpoint), and is involved in delaying damaged cells prior premitotic chromosome condensation (the G2 and pre-meiotic check-points) and actual chromosome partition (the spindle check-point). During these delays, an opportunity is given to repair the DNA damage, before its fixation and propagation, that may lead to carcinogenesis. Upon high or irreparable DNA damage, p53 promotes the cells towards apoptosis. Here we review the known molecular pathways by which p53 controls the cell cycle, with a specific focus on the significance of p53-mediated checkpoint response for its 'tumor suppressor' function. The data reviewed is concerned with the in vivo mouse models including p53 knockout mice, transgenic mice harboring various mutant forms of p53 and mice knocked out for cell-cycle- and apoptosis-associated genes situated upstream or downstream from p53, that have been elaborated upon over the last few years.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10101798     DOI: 10.1006/scbi.1998.0095

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  35 in total

Review 1.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

3.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 5.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

6.  Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk.

Authors:  Yu-Chao Lin; Wen-Shin Chang; Te-Chun Shen; Hsin-Ting Li; Chia-Hsiang Li; Yu-Chen Hsiau; Yun-Chi Wang; Cheng-Nan Wu; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 7.  Gene therapy in head and neck cancer: a review.

Authors:  E Chisholm; U Bapat; C Chisholm; G Alusi; G Vassaux
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

8.  p53 checkpoint ablation exacerbates the phenotype of Hinfp dependent histone H4 deficiency.

Authors:  Prachi N Ghule; Rong-Lin Xie; Jennifer L Colby; Stephen N Jones; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  Cell Cycle       Date:  2015-06-01       Impact factor: 4.534

9.  Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia.

Authors:  Miguel A de la Fuente; Mike Recher; Nicholas L Rider; Kevin A Strauss; D Holmes Morton; Margaret Adair; Francisco A Bonilla; Hans D Ochs; Erwin W Gelfand; Itai M Pessach; Jolan E Walter; Alejandra King; Silvia Giliani; Sung-Yun Pai; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2011-05-13       Impact factor: 10.793

10.  Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

Authors:  G P Feeney; R J Errington; M Wiltshire; N Marquez; S C Chappell; P J Smith
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.